Dalvinder Mandair

Dalvinder Mandair

Auto-generated profile, based on publicly available information

Dalvinder Mandair

Neuroendocrine Tumour Unit, ENETS Centre of Excellence, Royal Free Hospital, London, UK

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2012 in Best Practice & Research Clinical Gastroenterology
Verified
Journal Article
Closed access
DMDalvinder Mandair
Dalvinder Mandair
MCMartyn E. Caplin
Martyn E. Caplin

1 December 2014
Verified
Journal Article
Closed access
Roberta Elisa RossiRoberta Elisa Rossi
Roberta Elisa Rossi
MPMarinos Pericleous
Marinos Pericleous
DMDalvinder Mandair
Dalvinder Mandair
TWTara Whyand
Tara Whyand
MCMartyn Caplin
Martyn Caplin

1 January 2014
Verified
Journal Article
Closed access
MPMarinos Pericleous
Marinos Pericleous
Roberta Elisa RossiRoberta Elisa Rossi
Roberta Elisa Rossi
DMDalvinder Mandair
Dalvinder Mandair
TWTara Whyand
Tara Whyand
MCMartyn Caplin
Martyn Caplin

21 September 2022 in Scientific Reports
Verified
Journal Article
Open access
PDF file
DMDalvinder Mandair
Dalvinder Mandair
LKLukasz Kamieniarz
Lukasz Kamieniarz
MPMichail Pizanias
Michail Pizanias
MWMartin O. Weickert
Martin O. Weickert
ANAkshay Narayan
Akshay Narayan
CTChristos Toumpanakis
Christos Toumpanakis
Duodenal neuroendocrine neoplasms (dNENs) are rare neoplasms but their incidence is on the rise. They are classified into 5 sub-types but there remains much heterogeneity in behaviour in particular of non-functioning dNENs. To retrospectively analyse outcomes for all types of dNENs, and highlight prognostic factors associated with worse outcome. 102 (57 m/45f.) patients were identified with mean age at diagnosis 62 (range 32–87) years. The majority were non-functioning tumours 87/102 and median size was 10 mm (range 0.9–130 mm). 83 patients had Stage I or II disease, of which 17 underwent endoscopic resection with R1 rate of 45% and complication rate 12%. 36 patients were kept under endoscopic surveillance. There were 11 deaths of which 4 were disease related. Age and Ki67 > 20% were associated with worse OS in all dNENs. In non-functioning dNENs Ki67 > 3% was a predictor of lymph nodes metastases with OR 18.2 (2.54–13) (p < 0.005) in univariate analyses and liver metastases with OR 6.79 (1.56–29.5) (p < 0.05) in the multivariate analysis. Lesions 11–20 mm in size had OR 11.1 (1.16–106) compared to lesions < 11 mm for the prediction of lymph node metastases in the multivariate analysis (p < 0.05). ROC analysis of size of non-functioning dNENs to predict LN metastases found < 15 mm had an AUROC of 0.9 (0.81–0.99) with a sensitivity of 85% and specificity of 88%. dNENs are increasing in incidence, however low grade and smaller lesions have an indolent course and the role of endoscopic resection and active surveillance needs to be reviewed.

12 November 2020 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
PDF file
DMDalvinder Mandair
Dalvinder Mandair
MKMohid S Khan
Mohid S Khan
ALAndre Lopes
Andre Lopes
LOLuke Furtado O’mAhony
Luke Furtado O’mAhony
LELeah Ensell
Leah Ensell
TMTim Meyer
Tim Meyer
Background: Circulating tumor cells (CTCs) are detectable in patients with neuroendocrine tumors (NETs) and are accurate prognostic markers although the optimum threshold has not been defined. Objective: This work aims to define optimal prognostic CTC thresholds in PanNET and midgut NETs. Patients and Methods: CellSearch was used to enumerate CTCs in 199 patients with metastatic pancreatic (PanNET) (90) or midgut NETs (109). Patients were followed for progression-free survival (PFS) and overall survival (OS) for a minimum of 3 years or until death. Results: The area under the receiver operating characteristic curve (AUROC) for progression at 12 months in PanNETs and midgut NETs identified the optimal CTC threshold as 1 or greater and 2 or greater, respectively. In multivariate logistic regression analysis, these thresholds were predictive for 12-month progression with an odds ratio (OR) of 6.69 (P < .01) for PanNETs and 5.88 (P < .003) for midgut NETs. The same thresholds were found to be optimal for predicting death at 36 months, with an OR of 2.87 (P < .03) and 5.09 (P < .005) for PanNETs and midgut NETs, respectively. In multivariate Cox hazard regression analysis for PFS in PanNETs, 1 or greater CTC had a hazard ratio (HR) of 2.6 (P < .01), whereas 2 or greater CTCs had an HR of 2.25 (P < .01) in midgut NETs. In multivariate analysis OS in PanNETs, 1 or greater CTCs had an HR of 3.16 (P < .01) and in midgut NETs, 2 or greater CTCs had an HR of 1.73 (P < .06). Conclusions: The optimal CTC threshold to predict PFS and OS in metastatic PanNETs and midgut NETs is 1 and 2, respectively. These thresholds can be used to stratify patients in clinical practice and clinical trials.

13 May 2022 in Current Oncology Reports
Verified
Journal Article
Open access
PDF file
GRGowri Malka Ratnayke
Gowri Malka Ratnayke
FLFaidon-Marios Laskaratos
Faidon-Marios Laskaratos
DMDalvinder Mandair
Dalvinder Mandair
MCMartyn Caplin
Martyn Caplin
KRKrista Rombouts
Krista Rombouts
Christos ToumpanakisChristos Toumpanakis
Christos Toumpanakis
Purpose of Review: Mesenteric desmoplasia in small intestinal neuroendocrine neoplasms (SINENs) is associated with increased morbidity and mortality. In this paper, we discuss the development of desmoplasia in SINENs. Recent Findings: The fibrotic reactions associated with these tumours could be limited to the loco-regional environment of the tumour and/or at distant sites. Mesenteric fibrotic mass forms around a local lymph node. Formation of desmoplasia is mediated by interactions between the neoplastic cells and its microenvironment via number of profibrotic mediators and signalling pathways. Profibrotic molecules that are mainly involved in the desmoplastic reaction include serotonin, TGFβ (transforming growth factor β) and CTGF (connective tissue growth factor), although there is some evidence to suggest that there are a number of other molecules involved in this process. Summary: Desmoplasia is a result of autocrine and paracrine effects of multiple molecules and signalling pathways. However, more research is needed to understand these mechanisms and to develop targeted therapy to minimise desmoplasia.